{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:23:04Z","timestamp":1789042984923,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["11270"],"award-info":[{"award-number":["11270"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["13058"],"award-info":[{"award-number":["13058"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["15595"],"award-info":[{"award-number":["15595"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["14459"],"award-info":[{"award-number":["14459"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59818-8","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:16:02Z","timestamp":1747642562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation"],"prefix":"10.1038","volume":"16","author":[{"given":"Thomas","family":"Kimman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2261-7792","authenticated-orcid":false,"given":"Marta","family":"Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph G.","family":"Tieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedeke","family":"Rockx-Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmijn","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Motais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Slomp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Pleijte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heijhuurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo D.","family":"Meringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-1391","authenticated-orcid":false,"given":"Wendy","family":"Boschloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-8649","authenticated-orcid":false,"given":"Douwe M. T.","family":"Bosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8900-1285","authenticated-orcid":false,"given":"Sanne","family":"Kroos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"lo Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2088-9102","authenticated-orcid":false,"given":"Joost P. G.","family":"Sluijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-4456","authenticated-orcid":false,"given":"Niels","family":"Bovenschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-7806","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Kuball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"van Mil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6184-7676","authenticated-orcid":false,"given":"Zsolt","family":"Sebesty\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9011-3820","authenticated-orcid":false,"given":"Victor","family":"Peperzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"59818_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"59818_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"59818_CR3","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/blood.2021012811","volume":"139","author":"R Sakemura","year":"2022","unstructured":"Sakemura, R. et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood 139, 3708\u20133721 (2022).","journal-title":"Blood"},{"key":"59818_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145\u2013161 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"59818_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick, K., O\u2019Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. Annu Rev. Med 68, 139\u2013152 (2017).","journal-title":"Annu Rev. Med"},{"key":"59818_CR6","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","volume":"12","author":"YG Lee","year":"2022","unstructured":"Lee, Y. G. et al. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. Cancer Discov. 12, 2372\u20132391 (2022).","journal-title":"Cancer Discov."},{"key":"59818_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-022-00915-1","volume":"7","author":"X Yan","year":"2022","unstructured":"Yan, X. et al. Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Signal Transduct. Target Ther. 7, 98 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"59818_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019002121","volume":"135","author":"O Dufva","year":"2020","unstructured":"Dufva, O. et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood 135, 597\u2013609 (2020).","journal-title":"Blood"},{"key":"59818_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552\u2013567 (2020).","journal-title":"Cancer Discov."},{"key":"59818_CR10","doi-asserted-by":"crossref","unstructured":"Kimman, T. et al. Serpin B9 controls tumor cell killing by CAR T cells. J. Immunother. Cancer 11 (2023).","DOI":"10.1136\/jitc-2022-006364"},{"key":"59818_CR11","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","volume":"78","author":"N van Nieuwenhuijzen","year":"2018","unstructured":"van Nieuwenhuijzen, N. et al. From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer Res. 78, 2449\u20132456 (2018).","journal-title":"Cancer Res."},{"key":"59818_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-025-01675-5","volume":"18","author":"H Zheng","year":"2025","unstructured":"Zheng, H. et al. BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting. J. Hematol. Oncol. 18, 23 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"59818_CR13","doi-asserted-by":"crossref","unstructured":"Susanibar Adaniya, S. et al. CAR T cell therapy for multiple myeloma: what have we learned?. Leukemia 36 (2022).","DOI":"10.1038\/s41375-022-01539-8"},{"key":"59818_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1158\/0008-5472.CAN-11-2781","volume":"72","author":"RE Tiedemann","year":"2012","unstructured":"Tiedemann, R. E. et al. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res. 72, 757\u2013768 (2012).","journal-title":"Cancer Res."},{"key":"59818_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fonc.2018.00533","volume":"8","author":"A Slomp","year":"2018","unstructured":"Slomp, A. & Peperzak, V. Role and regulation of pro-survival BCL-2 proteins in multiple myeloma. Front Oncol. 8, 533 (2018).","journal-title":"Front Oncol."},{"key":"59818_CR16","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","volume":"19","author":"S Wuill\u00e8me-Toumi","year":"2005","unstructured":"Wuill\u00e8me-Toumi, S. et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19, 1248\u20131252 (2005).","journal-title":"Leukemia"},{"key":"59818_CR17","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","volume":"67","author":"P Gomez-Bougie","year":"2007","unstructured":"Gomez-Bougie, P. et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 67, 5418\u20135424 (2007).","journal-title":"Cancer Res."},{"key":"59818_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/14728222.2017.1349754","volume":"21","author":"JE Guikema","year":"2017","unstructured":"Guikema, J. E., Amiot, M. & Eldering, E. Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. Expert Opin. Ther. Targets 21, 767\u2013779 (2017).","journal-title":"Expert Opin. Ther. Targets"},{"key":"59818_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477\u2013482 (2016).","journal-title":"Nature"},{"key":"59818_CR20","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","volume":"3","author":"A Slomp","year":"2019","unstructured":"Slomp, A. et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 3, 4202\u20134214 (2019).","journal-title":"Blood Adv."},{"key":"59818_CR21","doi-asserted-by":"publisher","first-page":"6217","DOI":"10.1073\/pnas.0701297104","volume":"104","author":"PE Czabotar","year":"2007","unstructured":"Czabotar, P. E. et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc. Natl Acad. Sci. USA 104, 6217\u20136222 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59818_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1101\/gad.215855.113","volume":"27","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 27, 1351\u20131364 (2013).","journal-title":"Genes Dev."},{"key":"59818_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101015","volume":"23","author":"ML Rasmussen","year":"2020","unstructured":"Rasmussen, M. L. et al. MCL-1 inhibition by selective BH3 mimetics disrupts mitochondrial dynamics causing loss of viability and functionality of human cardiomyocytes. iScience 23, 101015 (2020).","journal-title":"iScience"},{"key":"59818_CR24","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1039\/D3BM01908J","volume":"12","author":"J Janssen","year":"2024","unstructured":"Janssen, J. et al. Hypothermic and cryogenic preservation of cardiac tissue-engineered constructs. Biomater. Sci. 12, 3866\u20133881 (2024).","journal-title":"Biomater. Sci."},{"key":"59818_CR25","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133\u20134141 (2012).","journal-title":"Blood"},{"key":"59818_CR26","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"key":"59818_CR27","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-10-0735","volume":"70","author":"SP Kerkar","year":"2010","unstructured":"Kerkar, S. P. et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70, 6725\u20136734 (2010).","journal-title":"Cancer Res."},{"key":"59818_CR28","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski, M. et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697\u20135706 (2011).","journal-title":"Cancer Res."},{"key":"59818_CR29","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang, L. et al. Arming CAR T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Mol. Ther. 31, 3146\u20133162 (2023).","journal-title":"Mol. Ther."},{"key":"59818_CR30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.omtm.2017.10.003","volume":"7","author":"DJ Woodsworth","year":"2017","unstructured":"Woodsworth, D. J. et al. Targeted cell-to-cell delivery of protein payloads via the granzyme-perforin pathway. Mol. Ther. Methods Clin. Dev. 7, 132\u2013145 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"59818_CR31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2527","volume":"14","author":"V Peperzak","year":"2013","unstructured":"Peperzak, V. et al. Mcl-1 is essential for the survival of plasma cells. Nat. Immunol. 14, 290\u2013297 (2013).","journal-title":"Nat. Immunol."},{"key":"59818_CR32","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1126\/science.1191793","volume":"330","author":"I Vikstrom","year":"2010","unstructured":"Vikstrom, I. et al. Mcl-1 is essential for germinal center formation and B cell memory. Science 330, 1095\u20131099 (2010).","journal-title":"Science"},{"key":"59818_CR33","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1126\/science.1106114","volume":"307","author":"JT Opferman","year":"2005","unstructured":"Opferman, J. T. et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307, 1101\u20131104 (2005).","journal-title":"Science"},{"key":"59818_CR34","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nature02067","volume":"426","author":"JT Opferman","year":"2003","unstructured":"Opferman, J. T. et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671\u2013676 (2003).","journal-title":"Nature"},{"key":"59818_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1101\/gad.14.1.23","volume":"14","author":"JL Rinkenberger","year":"2000","unstructured":"Rinkenberger, J. L., Horning, S., Klocke, B., Roth, K. & Korsmeyer, S. J. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 14, 23\u201327 (2000).","journal-title":"Genes Dev."},{"key":"59818_CR36","doi-asserted-by":"publisher","first-page":"1226289","DOI":"10.3389\/fonc.2023.1226289","volume":"13","author":"SI Tantawy","year":"2023","unstructured":"Tantawy, S. I., Timofeeva, N., Sarkar, A. & Gandhi, V. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Front. Oncol. 13, 1226289 (2023).","journal-title":"Front. Oncol."},{"key":"59818_CR37","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41589-021-00932-1","volume":"18","author":"TJ Gardner","year":"2022","unstructured":"Gardner, T. J. et al. Engineering CAR T cells to activate small-molecule drugs in situ. Nat. Chem. Biol. 18, 216\u2013225 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"59818_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2010-12-325993","volume":"118","author":"V Marco-Malina","year":"2011","unstructured":"Marco-Malina, V. et al. Redirecting \u03b1\u03b2 T cells against cancer cells by transfer of a broadly tumor-reactive \u03b3\u03b4T-cell receptor. Blood 118, 50\u201359 (2011).","journal-title":"Blood"},{"key":"59818_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171396","volume":"134","author":"F Sun","year":"2024","unstructured":"Sun, F. et al. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J. Clin. Invest. 134, e171396 (2024).","journal-title":"J. Clin. Invest."},{"key":"59818_CR40","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.7150\/thno.32058","volume":"9","author":"S Hamad","year":"2019","unstructured":"Hamad, S. et al. Generation of human induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer and scalable 3D suspension bioreactor cultures with reduced batch-to-batch variations. Theranostics 9, 7222\u20137238 (2019).","journal-title":"Theranostics"},{"key":"59818_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44873-4","volume":"15","author":"F Sun","year":"2024","unstructured":"Sun, F. et al. Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat. Commun. 15, 615 (2024).","journal-title":"Nat. Commun."}],"updated-by":[{"DOI":"10.1038\/s41467-026-71859-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59818-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59818-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59818-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:36:59Z","timestamp":1776145019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59818-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59818"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59818-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"21 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-026-71859-1","URL":"https:\/\/doi.org\/10.1038\/s41467-026-71859-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.P. received royalty payments related to venetoclax. V.P., Z.S., and T.K. are inventors on a patent for improving cytotoxicity of gene engineered T and NK cells. M.C.M. received research funding from Beigene, Janssen Cilag, Speakers fee from Janssen Cilag, Siemens, and Pfizer, and Consultancy fee from Janssen Cilag, Pfizer, BMS, and Hospitality Janssen Cilag, Beigene, all paid to institution. Z.S. and J.K. are inventors on different patents for \u03b3\u03b4 T-cell receptor sequences, recognition mechanisms, and isolation strategies. J.K. is the founder and shareholder of Gadeta Founders BV. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4638"}}